Project Grant R01CA298002
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$969K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $566,523 to support research on identifying interception targets in persistent lung premalignant lesions that are at risk of progressing to lung cancer. The research aims to leverage clinical trial data and human-relevant mechanistic studies to determine how prevention agents can target the persistence pathways underlying the most high-risk...
The University of North Carolina at Chapel Hill received a $657,536 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to study the burden and impact of false-positive results from lung cancer screening (LCS) using low-dose computed tomography (LDCT). The primary objectives are to: 1) identify attitudes, knowledge, and experiences with false-positive LCS results among patients and clinicians; 2) determine factors affecting false-positive...
The federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on developing noninvasive imaging and blood-based biomarkers to improve prediction of immunotherapy response and clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC). The $1,820,020 award, which runs from May 2024 to April 2029, will support research to: (1) create knowledge-guided radiomics and deep...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $602,315.00 to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test new lung cancer prevention agents. The key objectives are to: 1) Define the human relevance of the in vivo NTCU/smoke mouse model of lung SCC premalignancy, 2) Validate an ex vivo precision-cut lung slice approach to screen new prevention agents using...
The National Cancer Institute (NCI) has awarded a $1,853,375 Cooperative Agreement grant under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Utah. The project, titled "Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers", aims to increase the reach and equity of lung cancer screening among underserved populations. The two-phase, sequential multiple assignment randomized trial (SMART) will...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research. The grant funds a 5-year research project aimed at improving risk stratification and clinical management of non-small cell lung cancer (NSCLC) by developing multimodal predictive models incorporating real-world data from circulating tumor DNA sequencing, radiomics, tumor genomics, and electronic health...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research at the University of North Carolina at Chapel Hill to investigate the impact of NRF2 signaling on lung squamous cell carcinoma (LUSC) development. The project will utilize a novel genetically-engineered mouse model to assess how NRF2 activation affects LUSC incidence, tumor characteristics, and the tumor microenvironment. The total funding of $158,365 will be...
This $158,290 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a study to estimate the extent of overdiagnosis of lung cancer among patients receiving lung cancer screening in community-based healthcare settings. The study aims to produce a range of overdiagnosis estimates for this population, which may differ from the estimates derived from randomized controlled trials. The research will be conducted by Kaiser Foundation...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will support the University of South Carolina's investigation of novel targeted therapies, effects of comorbidities, and multi-level contributors to racial, socioeconomic, and rural disparities in lung and colon cancer survival trajectories. With $334,233 in funding over the project period of September 2024 to August 2029, the research will leverage...
This $230,010 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by the University of Chicago to investigate the drivers of metastasis in small cell lung cancer (SCLC). The researchers aim to leverage human pluripotent stem cell-derived lung cancer models, patient samples, and advanced technologies like single-cell sequencing to uncover the cellular and molecular mechanisms underlying SCLC's aggressive metastatic...